Diethylene Glycol Monoethyl Ether Versus Propylene Glycol and Their Impact on Topical Clobetasol Propionate Drug Delivery

Main Article Content

Leon Kircik MD
Icahn School of Medicine at Mount Sinai, New York, NY

Ryan Hartung PhD
Primus Pharmaceuticals, Inc., Scottsdale, AZ

Garrett Campbell
Primus Pharmaceuticals, Inc., Scottsdale, AZ

Ewa Hawkins MD PhD
Primus Pharmaceuticals, Inc., Scottsdale, AZ

Keywords

Plaque Psoriasis, Clobetasol

References

1. Osborne DW, Musakhanlan J. Skin Penetration and Permeation Properties of Transcutol - Neat or Diluted Mixtures. AAPS Pharm Sci Tech 2018;19(8):3512-3533.

2. Del Ross JQ. Topical Corticosteroid Therapy for Psoriasis - A Review of Clobetasol Propionate 0.025% Cream and the Relevance of Penetration Modification. J Clin Aesthetic Dermatol 2020;13(2):22-29.

3. Draelos ZD, Fowler JF, Cornelison R. A Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing with Clobetasol Propionate Cream (Impoyz), 0.025% versus Clobetasol Propionate (Temovate) Cream, 0.05% in Subjects with Moderate to Severe Plaque Psoriasis. Skin 2018;2(6):410-420.

Article Sidebar

Poster PDF
Published
May 20, 2023
DOI https://doi.org/10.25251/skin.7.supp.217

Article Details

How to Cite
Kircik MD, L., Hartung PhD, R., Campbell, G., & Hawkins MD PhD, E. (2023). Diethylene Glycol Monoethyl Ether Versus Propylene Glycol and Their Impact on Topical Clobetasol Propionate Drug Delivery. SKIN The Journal of Cutaneous Medicine, 7(3), s217. https://doi.org/10.25251/skin.7.supp.217
Issue
Vol. 7 No. 3 (2023): May Issue and Posters from WCH23 & WCM23
Section
Dermatopharmacology
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.